Skip to content

How it works

Semaglutide vs Tirzepatide: Which Works Better for Weight Loss?

Semaglutide (Ozempic, Wegovy) targets one receptor; tirzepatide (Mounjaro) targets two. In the only head-to-head trial, tirzepatide produced −20.2% body weight vs −13.7% for semaglutide at 72 weeks.

Last checked September 14, 2026·14 sources cited·Ozempic Wegovy Mounjaro Zepbound

Isometric clay scene of a terracotta and a sage injection pen balanced on a scale beside two molecular bead chains.

Semaglutides.org provides information only, not medical advice. Talk to a licensed provider about your own care before making changes. Some telehealth links are affiliate links and are labeled where they appear.

Semaglutide and tirzepatide are two different molecules, not two brands of the same drug. Semaglutide is a GLP-1 receptor agonist, meaning it activates one receptor: the glucagon-like peptide-1 receptor ^[6]^[8]. Tirzepatide is a dual agonist that activates both the GLP-1 receptor and a second receptor called GIP (glucose-dependent insulinotropic peptide), which has earned it the nickname “twincretin” as the first drug in its class ^[3].

On the question of which works better for weight loss, there is now one randomized head-to-head answer. In the SURMOUNT-5 trial, adults with obesity but without type 2 diabetes lost an average of 20.2% of their body weight on tirzepatide versus 13.7% on semaglutide over 72 weeks — a difference of about 6.5 percentage points, or 22.8 kg versus 15.0 kg ^[1]^[2]. Tirzepatide was superior for reduction in both body weight and waist circumference at 72 weeks ^[1].

What is the difference between GLP-1 and GIP?

GLP-1 and GIP are both incretin hormones — signals your gut releases after eating. Native GLP-1 is extremely short-lived: its plasma half-life is 1 to 2 minutes, because it is rapidly broken down by the DPP-4 enzyme and cleared by the kidneys ^[7]. That fragility is why drug developers modify GLP-1 analogs with fatty-acid side chains, a standard strategy to extend half-life and stability ^[7].

Semaglutide works only at the GLP-1 receptor ^[6]^[8]. Tirzepatide is a synthetic peptide analog of the human GIP hormone that also activates the GLP-1 receptor; it carries a C20 fatty-diacid portion attached through acylation, which lets it bind albumin and last long enough for a half-life of about five days and once-weekly injection ^[3].

Is Mounjaro a GLP-1?

Partly. Mounjaro is the brand name for tirzepatide, developed by Eli Lilly and approved by the FDA in May 2022 for type 2 diabetes ^[3]. Because tirzepatide activates the GLP-1 receptor in addition to the GIP receptor, calling it a “GLP-1” is incomplete — it is more accurately described as a dual GIP and GLP-1 receptor agonist ^[3].

On the semaglutide side, Ozempic is the semaglutide injection labeled for type 2 diabetes ^[6]. Wegovy is a semaglutide label that covers both an injection and oral tablets; the indications listed on the label — weight management, cardiovascular risk, and liver fibrosis — are stated for the injection ^[8]. Semaglutide’s initial US approval was 2017, and the Ozempic label is packaged by Novo Nordisk Pharmaceutical Industries, LP ^[6]^[8].

Why is tirzepatide more effective than semaglutide?

The honest answer is that the mechanism is not fully established. What researchers have documented is how tirzepatide behaves at each receptor, and the key mechanistic papers come from Lilly-affiliated authors ^[4]^[5].

A receptor-occupancy analysis found that at clinically efficacious doses, tirzepatide engages the GIP receptor more than the GLP-1 receptor — what the authors call an “imbalanced” mechanism of action ^[4]. At the GIP receptor, tirzepatide mimics native GIP. At the GLP-1 receptor, it is “biased”: it favors cAMP generation over β-arrestin recruitment, and it drives weaker receptor internalization than GLP-1 itself ^[4]. In primary islets, β-arrestin1 limits the insulin response to GLP-1 but not to GIP or tirzepatide ^[4].

The authors’ own framing is hedged: imbalance toward the GIP receptor, combined with distinct signaling at the GLP-1 receptor, “may account for” the drug’s promising efficacy ^[4]. Early-phase trials in type 2 diabetes had indicated tirzepatide improves outcomes beyond a selective GLP-1 receptor agonist ^[4]. Structural work has since studied the structural basis of tirzepatide’s dual receptor agonism ^[5]. So the dual-receptor design is real and measurable; whether it fully explains the weight-loss gap is still hypothesis, not settled clinical explanation.

What were the head-to-head weight loss results?

SURMOUNT-5 was a phase 3b, open-label trial that randomly assigned 751 adults in a 1:1 ratio to the maximum tolerated dose of tirzepatide (10 mg or 15 mg) or semaglutide (1.7 mg or 2.4 mg), both as once-weekly subcutaneous injections for 72 weeks ^[1]. Participants had obesity without type 2 diabetes — a BMI of 30 kg/m² or higher, or 27 kg/m² or higher with at least one obesity-related complication — across 32 sites in the US and Puerto Rico between April 2023 and November 2024 ^[2]. Mean age was 45 ^[2].

Measure at week 72	Tirzepatide	Semaglutide
Percent weight change (least-squares mean)	−20.2% (95% CI −21.4 to −19.1)	−13.7% (95% CI −14.9 to −12.6)
Average weight lost	22.8 kg	15.0 kg
Waist circumference change	−18.4 cm (95% CI −19.6 to −17.2)	−13.0 cm (95% CI −14.3 to −11.7)

Both comparisons were statistically significant at P<0.001 ^[1]^[2]. The tirzepatide group was also more likely to hit weight reductions of at least 10%, 15%, 20%, and 25% ^[1]. The trial was published in the New England Journal of Medicine online on May 11, 2025, and in the July 3, 2025 issue ^[1].

One wrinkle: weight loss was about 6% lower in men than in women in both groups, and the trial was 35% men — a higher share than most obesity trials. The authors suggest this may explain why the numbers were slightly lower than in earlier trials of each drug ^[2].

How solid is this evidence?

Worth knowing the limits before treating the headline numbers as a personal forecast:

The trial was open-label — participants knew which drug they were getting, which can influence reported outcomes ^[1].
The semaglutide comparator was capped at the maximum tolerated in-trial dose of 1.7 mg or 2.4 mg ^[1].
People with type 2 diabetes were excluded, so the results do not directly describe that population ^[1]^[2].
The trial was funded by Eli Lilly, the manufacturer of tirzepatide, and several authors were Lilly employees ^[1].

These are group averages, not individual predictions. An accompanying editorial by Frank L. Greenway, MD, raised the question of which body constituents are lost and why that may vary by sex ^[2]. No head-to-head body-composition comparison between the two drugs has been published.

Are the side effects different?

In the head-to-head trial, the most common adverse events in both groups were gastrointestinal, mostly mild to moderate, and mainly during dose escalation ^[1]. Gastrointestinal events caused discontinuation in 5.6% of the semaglutide group versus 2.7% of the tirzepatide group — roughly twice as often with semaglutide ^[2].

For semaglutide specifically, the Ozempic label lists nausea, vomiting, diarrhea, abdominal pain, and constipation as the most common adverse reactions, each reported in at least 5% of patients ^[6]. Both semaglutide labels carry a boxed warning: semaglutide causes thyroid C-cell tumors in rodents, and human relevance has not been determined. It is contraindicated with a personal or family history of medullary thyroid carcinoma or MEN 2 ^[6]^[8].

The semaglutide label also warns about acute pancreatitis, diabetic retinopathy complications, hypoglycemia when combined with insulin or insulin secretagogues, acute kidney injury from volume depletion, severe gastrointestinal reactions (not recommended in severe gastroparesis), hypersensitivity, gallbladder disease, and pulmonary aspiration during anesthesia or deep sedation ^[6]. Because semaglutide delays gastric emptying, it may affect absorption of oral medications ^[6]. The label advises discontinuing semaglutide at least 2 months before a planned pregnancy because of the long washout period ^[6].

Which one is approved for heart, kidney or liver conditions?

The labels diverge here, and an indication proven for one molecule does not transfer to the other.

Ozempic (semaglutide) is indicated for glycemic control in adults with type 2 diabetes, to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes and established cardiovascular disease, and to reduce the risk of sustained eGFR decline, end-stage kidney disease, and cardiovascular death in adults with type 2 diabetes and chronic kidney disease ^[6].

Wegovy (semaglutide) is indicated to reduce the risk of major adverse cardiovascular events — cardiovascular death, non-fatal heart attack, or non-fatal stroke — in adults with established cardiovascular disease plus obesity or overweight; for weight management in adults and pediatric patients aged 12 and older with obesity, and adults with overweight plus at least one weight-related comorbid condition; and for noncirrhotic MASH with moderate to advanced liver fibrosis (stages F2 to F3) in adults ^[8].

Tirzepatide’s US approval context in these sources is type 2 diabetes, as Mounjaro, in May 2022 ^[3].

How do the injections and dosing compare?

Both drugs in the head-to-head trial were once-weekly subcutaneous injections ^[1]. Semaglutide is also available as an oral tablet under the Wegovy label ^[8]. The Ozempic label states the injection can be given at any time of day, with or without meals, into the abdomen, thigh, or upper arm ^[6].

For reference only, as label information rather than a recommendation: the Ozempic label describes starting at 0.25 mg once weekly, increasing to 0.5 mg weekly after 4 weeks, then to 1 mg and 2 mg weekly if more glycemic control is needed, with at least 4 weeks at each step. A missed dose should be administered within 5 days. Pens come in 2 mg/3 mL, 4 mg/3 mL, and 8 mg/3 mL strengths, plus 0.25 mg, 0.5 mg, and 1 mg single-dose prefilled syringes, and a pen should never be shared between patients even with a new needle ^[6].

Dose decisions belong with a clinician. Nothing here is medical advice, and the right drug, dose, and escalation schedule depend on your health history and how you respond — questions to take to your prescriber.

How should you frame the choice?

The evidence supports three statements. First, in the only randomized head-to-head comparison, tirzepatide beat semaglutide on both weight and waist circumference at 72 weeks ^[1]. Second, semaglutide’s approved label reach is broad — type 2 diabetes glycemic control, cardiovascular risk reduction, chronic kidney disease outcomes, weight management including ages 12 and up, and noncirrhotic MASH with F2 to F3 fibrosis ^[6]^[8]. Third, both are once-weekly injections, with semaglutide also available as a tablet, and discontinuation for gastrointestinal reasons was about twice as common with semaglutide in the head-to-head ^[1]^[2]^[6]^[8].

Which drug fits a particular person is a decision for that person and their clinician — this page describes the published evidence, not a recommendation.

Sources

Frequently asked questions

Is tirzepatide stronger than semaglutide, and by how much?

In the only randomized head-to-head trial, tirzepatide produced −20.2% body weight versus −13.7% for semaglutide at 72 weeks — 22.8 kg versus 15.0 kg on average. Waist circumference fell 18.4 cm versus 13.0 cm. Both differences were statistically significant, but these are group averages, not individual forecasts.

Can you switch from one to the other?

The supplied sources do not publish switching guidance between semaglutide and tirzepatide. How to switch, at what dose, and over what period are decisions for a clinician, since the sources here cover trial results and label information rather than transition protocols.

Why does tirzepatide hit two receptors, and does that matter clinically?

Tirzepatide engages the GIP receptor more than the GLP-1 receptor and shows biased signaling at the GLP-1 receptor. Lilly-affiliated authors wrote this imbalance "may account for" its efficacy — a hypothesis, not an established clinical explanation. Early-phase type 2 diabetes trials showed outcomes beyond a selective GLP-1 receptor agonist.

Are the side effects different between the two?

In the head-to-head, both groups had mostly mild-to-moderate gastrointestinal events during dose escalation. Gastrointestinal events caused discontinuation in 5.6% of the semaglutide group versus 2.7% of the tirzepatide group. Semaglutide's label lists nausea, vomiting, diarrhea, abdominal pain, and constipation as most common.

Which one is approved for heart, kidney or liver conditions?

Semaglutide labels cover cardiovascular risk reduction, chronic kidney disease outcomes in type 2 diabetes, and noncirrhotic MASH with F2 to F3 fibrosis. The supplied sources state only that tirzepatide was approved as Mounjaro for type 2 diabetes in May 2022, so no fuller tirzepatide indication list can be given here.

Do men and women lose different amounts on these drugs?

In SURMOUNT-5, weight loss was about 6% lower in men than women in both treatment groups. The trial was 35% men, and the authors suggest this may explain why its numbers were slightly lower than earlier trials of each drug. An accompanying editorial raised questions about body composition and sex.

Is Ozempic the same as Wegovy, and is Mounjaro the same as Zepbound?

Ozempic and Wegovy are both semaglutide: Ozempic is the injection labeled for type 2 diabetes, while the Wegovy label covers a semaglutide injection and oral tablets, with its listed indications stated for the injection. Mounjaro is tirzepatide. The supplied sources do not support mapping other brand names, so no Zepbound or Rybelsus statements can be made here.

Was the head-to-head trial funded by a drug company?

Yes. SURMOUNT-5 was funded by Eli Lilly, the manufacturer of tirzepatide, and several trial authors were Lilly employees. The mechanistic papers on tirzepatide's dual agonism also involved Lilly Research Laboratories authors. The trial was published in the New England Journal of Medicine in 2025.

This article summarizes FDA labeling, published research and company information current as of September 14, 2026. It is not medical advice and does not replace a conversation with your own healthcare provider. How we research and verify.